Company Profiles

driven by the PitchBook Platform

Accium BioSciences

Description

Developer of an ultrasensitive detection platform designed to overcome challenges faced in clinical development of novel drugs. The company's ultrasensitive detection platform investigates pharmacologic and pharmacodynamic endpoints of Merck's Temodar® in glioblastoma multiforme (GBM) patients, providing 14C-methylation measurements of tumor DNA after 14C-Temodar® administration. The purpose of the study is to identify pharmacologic or pharmacodynamic endpoints that may be predictive of response to therapy in individual patients, enabling clinicians to involve therapeutic response prediction and resistance to treatment.

2004

Founded

PRIVATE

Status

11-50

Employees

Conv. Debt

Latest Deal Type

$250k

Latest Deal Amount

$3.61M

Total Amount Raised

Description

Developer of an ultrasensitive detection platform designed to overcome challenges faced in clinical development of novel drugs. The company's ultrasensitive detection platform investigates pharmacologic and pharmacodynamic endpoints of Merck's Temodar® in glioblastoma multiforme (GBM) patients, providing 14C-methylation measurements of tumor DNA after 14C-Temodar® administration. The purpose of the study is to identify pharmacologic or pharmacodynamic endpoints that may be predictive of response to therapy in individual patients, enabling clinicians to involve therapeutic response prediction and resistance to treatment.

Website:

www.acciumbio.com

Ownership Status

Privately held (backing)

Financing Status

Venture Capital-Backed

Primary Industry

Other Pharmaceuticals and Biotechnology

Other Industries

Social/Platform Software

Primary Office

550 17th Avenue Suite 550 Seattle, WA 98122United States +1 (206) 258-8860
Request a free trial to the PitchBook Platform
You're viewing a free company profile from the PitchBook Platform. To explore Accium BioSciences's full profile, request a free trial.

Accium BioSciences Valuation and Funding

Request access
Deal TypeDateAmountRaised to DatePost-ValStatusStage

Accium BioSciences Cap Table

Stock# of Shares
Authorized
Par ValueDividend Rate (%)Original
Issue Price
LiquidationLiquidation
Pref. Multiple
Conversion
Price
% Owned

Accium BioSciences Investors (3)

Request access
Investor NameInvestor TypeHoldingInvestor SinceParticipating RoundsBoard
Seat
Contact
Info
Alliance of AngelsAngel GroupMinority000 0000000 0000
SabeyCorporate Venture CapitalMinority000 0000000 0000
WRF CapitalVenture CapitalMinority000 0000000 0000
Alliance of Angels Angel Group
Sabey Corporate Venture Capital
WRF Capital Venture Capital

Accium BioSciences Executive Team (3)

NameTitleBoard
Seat
Contact
Info
Jonathan AdlerStudy Director
Glenn Kawasaki Ph.DChief Executive Officer & President
Barbara Alford-CasselVice President, Quality Assurance & Quality Assurance Officer
Jonathan Adler Study Director
Glenn Kawasaki Ph.D Chief Executive Officer & President
Barbara Alford-Cassel Vice President, Quality Assurance & Quality Assurance Officer
Request full access to PitchBook